Abbvie Inc
Research Abbvie Inc (ABBV) on Bullrun: valuation model: 34.6% overvalued, market cap USD 488.54B, P/E 78.2, dividend yield 2.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABBV
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal34.6% overvalued
- Market capUSD 488.54B
- P/E78.2
- Dividend yield2.4%
- Financial periodQ2 2026
- RevenueUSD 16.99B
- Net incomeUSD 3.61B
- Free cash flowUSD 3.11B
- Gross margin74.7%
Valuation Snapshot
Bullrun's latest valuation model marks Abbvie Inc as 34.6% overvalued; latest market cap is USD 488.54B; P/E is 78.2; dividend yield is 2.4%.
Peer valuation comparison
Latest P/E is 78.17x versus a Healthcare sector median of 24.61x (217.7% above).
Latest dividend yield is 2.43% versus a Healthcare sector median of 1.84% (32.1% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 61.16B | USD 4.23B | USD 17.82B | 70.2% | 2.36 | USD 5.23B | USD 67.00B | -USD 3.27B |
| FY2024 | USD 56.33B | USD 4.28B | USD 17.83B | 70.0% | 2.39 | USD 5.52B | USD 66.84B | USD 3.33B |
| FY2023 | USD 54.32B | USD 4.86B | USD 22.06B | 62.4% | 2.72 | USD 12.81B | USD 59.25B | USD 10.36B |
| FY2022 | USD 58.05B | USD 11.84B | USD 24.25B | 70.0% | 6.63 | USD 9.20B | USD 63.13B | USD 17.25B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 488.54B | 78.2 | 2.5% | 6.83 |
| 2025 | 2025-12-31 | USD 403.94B | 96.8 | 2.9% | 6.56 |
| 2024 | 2024-12-31 | USD 313.69B | 74.4 | 3.5% | 6.2 |
| 2023 | 2023-12-29 | USD 273.61B | 42.5 | 3.8% | 5.92 |
| 2022 | 2022-12-30 | USD 285.80B | 21.5 | 3.5% | 5.64 |
| 2021 | 2021-12-31 | USD 239.43B | 21.0 | 3.8% | 5.2 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 6.83 USD, yield 2.4%.
| Year | Dividends/share |
|---|---|
| FY2025 | 6.65 USD |
| FY2024 | 6.29 USD |
| FY2023 | 5.99 USD |
| FY2022 | 5.71 USD |
About Abbvie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
ETFs that hold Abbvie Inc
Abbvie Inc is one of the ten largest holdings of 93 ETFs that investors in Europe can buy. The 8 most traded of them:
| ETF | Weight | TER |
|---|---|---|
| Vanguard FTSE All-World High Dividend Yield UCITS ETF USD Distributing | 1.07% | 0.29% |
| Vanguard FTSE All-World High Di | 1.03% | 0.29% |
| iShares S&P 500 Health Care Sector UCITS ETF USD (Acc) | 7.75% | 0.15% |
| Xtrackers MSCI World Health Care UCITS ETF 1C | 5.40% | 0.25% |
| Amundi Global Memory Chips UCITS ETF Accumulation | 2.67% | 0.45% |
| State Street SPDR S&P 500 Leaders UCITS ETF | 1.82% | 0.03% |
| State Street SPDR S&P US Dividend Aristocrats UCITS ETF Dis | 1.62% | 0.35% |
| iShares Healthcare Innovation UCITS ETF USD (Acc) | 1.52% | 0.40% |
Compare every fund on the same index:
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Abbvie Inc overvalued or undervalued?
Bullrun's valuation model currently marks Abbvie Inc as 34.6% overvalued.
What is Abbvie Inc's market cap?
Abbvie Inc's market capitalization is USD 488.54B.
What is Abbvie Inc's P/E ratio?
Abbvie Inc's price-to-earnings (P/E) ratio is 78.2.
Does Abbvie Inc pay a dividend?
Abbvie Inc has a dividend yield of 2.4%.
What does Abbvie Inc do?
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.